Cellectis (CLLS) Current Deferred Tax Assets (2024)

Cellectis (CLLS) posted quarterly Current Deferred Tax Assets of $710000.0 for Q2 2024, up 73.59% quarter-over-quarter from $409000.0 in Q1 2024.

Cellectis (CLLS) Current Deferred Tax Assets (2024) Analysis & Trends

Cellectis' Current Deferred Tax Assets history runs 1 years deep, the most recent figure standing at $710000.0 for Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Cellectis	306.61 Mn	120.95 Mn	-

Download Data